Finished
Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy
NCT07415135 · Zhu Yinjie · Updated 30 Sept 2026
- What is being tested
- 0.02 mg/kg of DGPR1008 Injection was administered 24 hours before surgery; 0.04 mg/kg of DGPR1008 Injection was administered 24 hours before surgery; 0.06 mg/kg of DGPR1008 Injection was administered 24 hours before surgery
- For
- Prostate Cancer
- Kind of study
- Tests a treatment or device on volunteers. Phase 2.
- Who can join
- Ages 18 years and older. About 18 people. The full rules are on the registry page.
- Where
- China
- When
- Starts or started 20 March 2026, ends 29 Aug 2026. Registered 17 Feb 2026.
- Results
- None posted yet.
In the researchers' words
This study is a single-center, single-arm, open-label exploratory study to evaluate the safety and efficacy of fluorescent imaging combined with a robotic surgical control system for robot-assisted radical prostatectomy.
Sites
- RENJIShanghai, Shanghai Municipality, China